Form 4: Moderna CEO Stephane Bancel Reports Stock Option Grant

Moderna's CEO, Stephane Bancel, reported the acquisition of stock options and changes in beneficial ownership of Moderna shares.

Summary

• Stephane Bancel, CEO of Moderna, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report indicates that Bancel acquired stock options to purchase 357,065 shares of Moderna common stock at an exercise price of $30.96 on March 1, 2025.
• These options vest 25% on March 1, 2026, with the remainder vesting in equal quarterly installments over the following three years.
• Bancel also reported direct ownership of 5,493,897 shares of common stock.
• He also reported indirect ownership of 9,050,372 shares through Boston Biotech Ventures, LLC and 6,564,880 shares through OCHA LLC, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
• The filing was signed by James Dillon, as Attorney-in-Fact, on March 3, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This grant is typical for CEOs of publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Pfizer, BioNTech, and Johnson & Johnson also utilize stock options as part of their executive compensation plans.
• The vesting schedule of these options is fairly standard, with a typical vesting period of 3-4 years to incentivize long-term performance.

Stakeholder Impact

• The stock option grant aligns the CEO's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates